The “bivalent” vaccine — meaning it targets two different antigens — is Moderna’s leading candidate to have an effective booster ready for fall of 2022, the company said.
×
The “bivalent” vaccine — meaning it targets two different antigens — is Moderna’s leading candidate to have an effective booster ready for fall of 2022, the company said.